LB Pharmaceuticals (LBRX) Stock Price, News & Analysis

Company Overview

LB Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system and neuropsychiatric disorders. The company’s lead product candidate is LB-102, an oral prodrug of amisulpride, an established antipsychotic medicine that is approved in certain countries outside the United States but is not currently approved in the U.S.

LB-102 is being developed for the treatment of schizophrenia, with the company seeking to evaluate its potential to address the needs of patients and healthcare providers in the U.S. and other markets. LB Pharmaceuticals’ development activities are centered on advancing this candidate through clinical testing and regulatory review.

The company is headquartered in New York and is listed on the Nasdaq under the symbol LBRX. Publicly available information about its broader pipeline, international operations and leadership is limited.

Key Stats

• Today's Range: $36.06 to $37.37
• 50-Day Range: $34.00 to $49.48
• 52-Week Range: $14.32 to $50.16
• Volume: 724,736 shs
• Average Volume: 462,824 shs
• Market Capitalization: $1.19 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $57.40
• Consensus Rating: Moderate Buy

LB Pharmaceuticals Stock Analysis - MarketRank™

LB Pharmaceuticals scored higher than 48% of companies evaluated by MarketBeat, and ranked 593rd out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

LB Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 2 sell ratings.

Upside Potential

LB Pharmaceuticals has a consensus price target of $57.40, representing about 56.2% upside from its current price of $36.74.

Amount of Analyst Coverage

LB Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for LB Pharmaceuticals are expected to grow in the coming year, from ($5.70) to ($5.41) per share.

Price to Book Value per Share Ratio

LB Pharmaceuticals has a P/B Ratio of 3.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.78% of the float of LB Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

LB Pharmaceuticals has a short interest ratio ("days to cover") of 14.51, which indicates bearish sentiment.

Change versus previous month

Short interest in LB Pharmaceuticals has recently increased by 7.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LB Pharmaceuticals does not currently pay a dividend.

Dividend Growth

LB Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.61

News Sentiment

LB Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for LB Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for LBRX on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added LB Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LB Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.80% of the stock of LB Pharmaceuticals is held by insiders.

Percentage Held by Institutions

LB Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:LBRX
• CIK: 1691082
• Web: lbpharma.us
• Phone: (917) 450-6581
• Fax: N/A
• Employees: 27
• Year Founded: 2015

Price Target and Rating

• Average Price Target for LB Pharmaceuticals: $57.40
• High Price Target: $80.00
• Low Price Target: $35.00
• Potential Upside/Downside: +56.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.62
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -25.92%
• Return on Assets: -24.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.08
• Quick Ratio: 15.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.91 per share
• Price / Book: 3.08

Miscellaneous

• Outstanding Shares: 32,260,000
• Free Float: 30,388,000
• Market Cap: $1.19 billion
• Optionable: N/A
• Beta: N/A